PL3197442T3 - Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO - Google Patents
Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAOInfo
- Publication number
- PL3197442T3 PL3197442T3 PL15843415T PL15843415T PL3197442T3 PL 3197442 T3 PL3197442 T3 PL 3197442T3 PL 15843415 T PL15843415 T PL 15843415T PL 15843415 T PL15843415 T PL 15843415T PL 3197442 T3 PL3197442 T3 PL 3197442T3
- Authority
- PL
- Poland
- Prior art keywords
- tmao
- tma
- treating
- lowering agents
- preventing disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056168P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/052380 WO2016049541A2 (en) | 2014-09-26 | 2015-09-25 | Treating and preventing disease with tma and tmao lowering agents |
| EP15843415.9A EP3197442B1 (en) | 2014-09-26 | 2015-09-25 | Treating and preventing disease with tma and tmao lowering agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3197442T3 true PL3197442T3 (pl) | 2020-02-28 |
Family
ID=55582099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15843415T PL3197442T3 (pl) | 2014-09-26 | 2015-09-25 | Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US20160089386A1 (pl) |
| EP (2) | EP3569232A1 (pl) |
| CA (1) | CA2962424C (pl) |
| ES (1) | ES2747234T3 (pl) |
| PL (1) | PL3197442T3 (pl) |
| WO (2) | WO2016049537A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2925346A1 (fr) | 2012-11-30 | 2015-10-07 | Universite d'Auvergne Clermont I | Utilisation de microorganismes pour diminuer le taux de triméthylamine dans une cavité du corps humain, notamment pour le traitement de la triméthylaminurie ou d'une vaginose bactérienne et la prévention des maladies cardiovasculaires |
| US20160089386A1 (en) | 2014-09-26 | 2016-03-31 | The Cleveland Clinic Foundation | Treating and preventing disease with tma and tmao lowering agents |
| ES2974674T3 (es) * | 2017-06-19 | 2024-07-01 | Cleveland Clinic Found | Tratamiento de enfermedades y promoción de la pérdida de peso inhibiendo la vía TMA/FMO3/TMAO |
| SG11202001332YA (en) * | 2017-08-14 | 2020-03-30 | Psomagen Inc | Targeted drugs associated with trimethylamine and/or trimethylamine-n-oxide |
| WO2019152847A1 (en) * | 2018-02-01 | 2019-08-08 | The Cleveland Clinic Foundatoin | Disease detection and treatment based on trimethyl-lysine levels |
| CN108179128A (zh) * | 2018-03-12 | 2018-06-19 | 新疆农业大学 | 一种羔羊粪菌液的制备方法 |
| SG11202105533YA (en) * | 2018-12-06 | 2021-06-29 | Senda Biosciences Inc | Decarboxylase inhibitors for treating parkinson's disease |
| CN110279863B (zh) * | 2019-07-29 | 2022-02-22 | 牡丹江医学院 | 用于治疗泌尿疾病的药物组合物及其制剂 |
| CN111983112A (zh) * | 2020-09-09 | 2020-11-24 | 南京诺禾致源生物科技有限公司 | 血清中tmao及其相关代谢物的检测方法 |
| CN112029818A (zh) * | 2020-09-18 | 2020-12-04 | 中国药科大学 | 一种利用微生物筛选三甲胺裂解酶抑制剂的方法 |
| CN114763519B (zh) * | 2021-01-12 | 2025-07-22 | 生合生物科技股份有限公司 | 食淀粉乳杆菌lam1345分离株及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2676224B1 (fr) * | 1991-05-10 | 1996-08-02 | Jean Marie Gastaud | Nouveaux sels d'ammonium quaternaire, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant. |
| AU2001271248A1 (en) * | 2000-04-28 | 2001-11-12 | Duke University | 18f-labeled choline analogs |
| DE60225271T2 (de) * | 2001-05-09 | 2009-03-05 | Discoverx, Inc., Fremont | Screening auf enzyminhibitoren |
| DE10248619A1 (de) * | 2002-10-18 | 2004-04-29 | Bayer Ag | Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden |
| CN1615908B (zh) | 2003-10-22 | 2011-09-28 | 株式会社吴羽 | 口服给药用吸附剂、以及肾病治疗或预防剂、和肝病治疗或预防剂 |
| WO2006002151A1 (en) | 2004-06-21 | 2006-01-05 | Hemolife Medical, Inc. | Plasma detoxification and volume control system and methods of use |
| WO2007035596A2 (en) | 2005-09-19 | 2007-03-29 | Mastertaste Inc. | Metal organic framework odor sequestration and fragrance delivery |
| CN101157667A (zh) * | 2007-11-12 | 2008-04-09 | 天津工业大学 | 一种吗啉季铵盐型离子液体及其制备方法 |
| CN102458481A (zh) * | 2009-05-28 | 2012-05-16 | 克里夫兰诊所基金会 | 用于诊断和预测疾病的含三甲胺的化合物 |
| DE102010044131A1 (de) | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
| JP5992926B2 (ja) * | 2011-02-10 | 2016-09-14 | ザ クリーブランド クリニック ファウンデーションThe Cleveland ClinicFoundation | 心血管系疾患および血栓症の治療および予防のための組成物 |
| CN104582507A (zh) | 2012-06-11 | 2015-04-29 | 克利夫兰诊所基金会 | 心血管疾病和血栓形成的治疗与预防 |
| LV14848B (lv) * | 2012-10-25 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai |
| US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| US20160089386A1 (en) | 2014-09-26 | 2016-03-31 | The Cleveland Clinic Foundation | Treating and preventing disease with tma and tmao lowering agents |
| ES2974674T3 (es) * | 2017-06-19 | 2024-07-01 | Cleveland Clinic Found | Tratamiento de enfermedades y promoción de la pérdida de peso inhibiendo la vía TMA/FMO3/TMAO |
-
2015
- 2015-09-25 US US14/866,375 patent/US20160089386A1/en not_active Abandoned
- 2015-09-25 CA CA2962424A patent/CA2962424C/en active Active
- 2015-09-25 ES ES15843415T patent/ES2747234T3/es active Active
- 2015-09-25 WO PCT/US2015/052372 patent/WO2016049537A1/en not_active Ceased
- 2015-09-25 EP EP19172488.9A patent/EP3569232A1/en not_active Withdrawn
- 2015-09-25 US US14/866,398 patent/US9694020B2/en active Active
- 2015-09-25 PL PL15843415T patent/PL3197442T3/pl unknown
- 2015-09-25 EP EP15843415.9A patent/EP3197442B1/en active Active
- 2015-09-25 WO PCT/US2015/052380 patent/WO2016049541A2/en not_active Ceased
-
2017
- 2017-05-31 US US15/610,145 patent/US10117879B2/en active Active
-
2018
- 2018-10-12 US US16/159,102 patent/US20190038642A1/en not_active Abandoned
-
2019
- 2019-10-30 US US16/668,178 patent/US10933072B2/en active Active
-
2021
- 2021-03-02 US US17/189,551 patent/US11911399B2/en active Active
-
2024
- 2024-01-30 US US18/426,704 patent/US20240165131A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10933072B2 (en) | 2021-03-02 |
| US20240165131A1 (en) | 2024-05-23 |
| US20200197417A1 (en) | 2020-06-25 |
| CA2962424C (en) | 2024-04-30 |
| EP3197442B1 (en) | 2019-07-03 |
| US20190038642A1 (en) | 2019-02-07 |
| US20170266208A1 (en) | 2017-09-21 |
| ES2747234T3 (es) | 2020-03-10 |
| US20210186991A1 (en) | 2021-06-24 |
| US10117879B2 (en) | 2018-11-06 |
| US20160089387A1 (en) | 2016-03-31 |
| WO2016049541A2 (en) | 2016-03-31 |
| WO2016049541A3 (en) | 2016-06-16 |
| US11911399B2 (en) | 2024-02-27 |
| CA2962424A1 (en) | 2016-03-31 |
| EP3197442A4 (en) | 2018-04-04 |
| EP3197442A2 (en) | 2017-08-02 |
| US9694020B2 (en) | 2017-07-04 |
| WO2016049537A1 (en) | 2016-03-31 |
| US20160089386A1 (en) | 2016-03-31 |
| EP3569232A1 (en) | 2019-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255577B (en) | Binding materials - tigit and their uses | |
| IL253433A0 (en) | Binders - tnfrsf and their uses | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| IL249370A0 (en) | Fap-enabled medical substances and related uses | |
| EP3197442A4 (en) | Treating and preventing disease with tma and tmao lowering agents | |
| IL250331A0 (en) | Flagellin-based agents and uses including effective vaccination | |
| GB201506913D0 (en) | Inductor structure and application thereof | |
| LT3215147T (lt) | Neurologinį poveikį mažinantys norketamino junginiai ir būdai | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| PL3362449T3 (pl) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową | |
| GB201608779D0 (en) | Methods and compounds | |
| GB201616439D0 (en) | Compounds and uses | |
| IL255092A0 (en) | Combined treatments with srivantumab | |
| GB201608776D0 (en) | Methods and compounds | |
| IL252904A0 (en) | Methods and factors for treating diseases | |
| IL248424B (en) | Neuroprotective substances and their uses | |
| GB201404372D0 (en) | Assay and treatment | |
| PL3129398T3 (pl) | Nowe środki medyczne i ich zastosowanie | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| SG10201912843YA (en) | Sleep improving agent | |
| SG11201610349SA (en) | Dosing regimens for treating and/or preventing cerebral amyloidoses | |
| PT3150778T (pt) | Cadeira de suspensão em altura | |
| IL253435A0 (en) | Structures and methods for placement | |
| GB2530711B (en) | Security composition and use thereof | |
| GB201403262D0 (en) | Dog safety latch |